TORONTO, June 24, 2022 /CNW Telbec/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from June 27 – 28, 2022 in New York.

Source

Previous articlePT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women, Coaching, and Ketamine For Fibromyalgia
Next articleDiamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin